论文部分内容阅读
本文旨在研究非小细胞肺癌患者发生抑癌基因P53基因的突变量的状况，经采用PCR-SSCP法分析63例非小细胞肺癌和5例正常胎儿肺组织在外显予5、6、7和8中发生的点突变，NSCLC总突变率为49．2％（31／63）。5例正常胎肺组织未出现P53基因突变，63例NSCLC患者中，37例磷癌，16例为腺癌和10例鳞除混合癌，其突变率分别为48．6％，50％和50．0％，与肿瘤组织类型无关。Ⅰ期19例，Ⅱ期22例和Ⅲ例22例，其突变率分别为47.5％，45．4％和54．5％，Ⅲ期突变率稍高，但无统计学意义。本结果证明肺癌组织存在P53基因点突变可能为肺癌发生的关键基因之一。
The purpose of this study was to investigate the mutational status of tumor suppressor gene P53 in patients with non-small cell lung cancer. PCR-SSCP was used to analyze 63 cases of non-small cell lung cancer and 5 cases of normal fetal lung tissue in exon 5, 6, 7 and Among the 8 point mutations, the total mutation rate of NSCLC was 49.2% (31/63). 5 cases of normal fetal lung tissue did not show mutations in P53 gene, of 63 NSCLC patients, 37 cases of phosphorus cancer, 16 cases of adenocarcinoma and 10 cases of squamous cell carcinoma, the mutation rate was 48.6%, 50% and 50, respectively. .0%, regardless of the type of tumor tissue. There were 19 patients in stage I, 22 in stage II, and 22 in III. The mutation rates were 47.5%, 45.4%, and 54.5%, respectively. The mutation rate in stage III was slightly higher, but it was not statistically significant. The present results demonstrate that the point mutation of P53 gene in lung cancer may be one of the key genes for lung cancer.